Editor's Note: This article was written by Wayne Eskridge, founder of the Fatty Liver Foundation. When we are diagnosed with F4 MASH (cirrhosis) we are often told that it is…
As published in Sage Journals, researchers have developed an accessible, machine learning-driven histopathology workflow that enables quantitative evaluation of metabolic dysfunction-associated steatohepatitis (MASH) in laboratory mice without requiring coding expertise…
As reported on Bioengineer and ScienMag, a new spatial transcriptomics study has provided fresh insight into how different regions of the liver are remodeled during metabolic dysfunction-associated steatohepatitis (MASH). By…
Many people spend very little time contemplating their liver, often ignoring this critical organ until a major medical issue arises. In contrast, health culture in countries like France has long…
As reported on BioSpace, AstraZeneca has entered a major artificial intelligence-focused research collaboration with biotechnology company insitro, committing up to $1.5 billion in potential payments to identify new drug targets…
As reported on Medical Daily, small exploratory analysis suggests that semaglutide, the active ingredient in Wegovy, may substantially reduce liver fat in some adults with obesity. However, the findings come…
Semaglutide 2.4 mg becomes Singapore’s first approved therapy for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis. As reported on the Manila Times, Singapore’s Health Sciences Authority (HSA) has…
A recent report by the Manila Times highlighted Madrigal Pharmaceuticals' unveiling of a series of new analyses and real-world findings supporting the therapeutic profile of resmetirom (Rezdiffra) for metabolic dysfunction-associated…
As reported on MedicalXpress, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for several therapies this cycle, including a conditional endorsement…
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating continued weight loss and…
I'm Nella, and this is part of my journey with Metabolic dysfunction-associated steatohepatitis (MASH). I was diagnosed with MASH in early 2024, after being referred to a GI doctor…
Eccogene, a clinical-stage biopharmaceutical company, has announced enrollment of the first patient in MOSAIC, a Phase 2a clinical trial investigating two novel oral small molecules for treating metabolic dysfunction-associated steatohepatitis…
As reported by Healio, the U.S. Food and Drug Administration (FDA) has officially qualified AIM-MASH AI Assist, marking a milestone as the first artificial intelligence tool cleared to support drug…
Key Insight: As reported by Healio, metabolic dysfunction-associated steatotic liver disease (MASLD) is not exclusive to individuals with obesity. New research presented at The Liver Meeting reveals that lean patients…
As reported on Healio, new findings presented at The Liver Meeting highlight the potential of resmetirom (Rezdiffra, Madrigal Pharmaceuticals) in managing metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis—a population with…
At the 76th annual AASLD Liver Meeting®, Novo Nordisk presented new findings from a post hoc analysis of the ESSENCE phase 3 trial, highlighting the impact of semaglutide 2.4 mg…
My name is Danielle, and in 2021, I was diagnosed with Stage 3 MASH, a life-threatening liver disease. I consider myself lucky because I had no real symptoms; my MASH was…
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as fatty liver disease, affects about one in three adults worldwide and poses major health risks, not only for the liver but…
Your story has the power to educate, motivate, and make a real difference in the lives of others. We are looking for patients with Metabolic Dysfunction-Associated Steatohepatitis, or MASH –…
Your story has the power to educate, motivate, and make a real difference in the lives of others. We are looking for patients with Metabolic Dysfunction-Associated Steatohepatitis, or MASH –…
Your story has the power to educate, motivate, and make a real difference in the lives of others. We are looking for patients with Metabolic Dysfunction-Associated Steatohepatitis, or MASH -…
August 2025 was a landmark month for rare disease innovation, as the U.S. Food and Drug Administration (FDA) granted four historic approvals, each representing a first for their respective conditions,…
Acknowledgement: Patient Worthy is proud to share this article from our friends at the Fatty Liver Foundation. As a patient, what I really want to understand is how damaged is…
The U.S. Food and Drug Administration (FDA) reported the approval of semaglutide injections for metabolic dysfunction-associated steatohepatitis (MASH), marking a major milestone in the fight against this increasingly common and…
ACKNOWLEDGEMENT – Patient Worthy is honored to partner with The Fatty Liver Foundation to provide you with this article. The Fatty Liver Foundation aims to improve the diagnosis, treatment & support…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
